DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

2INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 670220-88-9, Crenolanib (cp-868596), Cp-868596, Aro-002, Crenolanib [usan], Cp-868,596

Molecular Formula

C₂₆H₂₉N₅O₂

Molecular Weight

443.5 g/mol

InChI Key

DYNHJHQFHQTFTP-UHFFFAOYSA-N

FDA UNII

LQF7I567TQ

Crenolanib is an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.

1 2D Structure

Crenolanib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine

2.1.2 InChI

InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3

2.1.3 InChI Key

DYNHJHQFHQTFTP-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4

2.2 Other Identifiers

2.2.1 UNII

LQF7I567TQ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cp-868,596

2.3.2 Depositor-Supplied Synonyms

1. 670220-88-9

2. Crenolanib (cp-868596)

3. Cp-868596

4. Aro-002

5. Crenolanib [usan]

6. Cp-868,596

7. Aro 002

8. Cp 868596

9. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine

10. Lqf7i567tq

11. Cp868569

12. Crenolanib (usan)

13. Mfcd21609260

14. 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine

15. 1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1h-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine

16. 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine

17. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine.

18. 1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1h-1,3-benzodiazol-1-yl}quinolin-8-yl)piperidin-4-amine

19. Cp-868

20. Cp868596

21. Crenolanib [usan:inn]

22. Unii-lqf7i567tq

23. Crenolanibum

24. Cp-868596 (crenolanib)

25. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzimidazol-1-yl)quinolin-8-yl)piperidin-4-amine

26. 6t2

27. Cp-868569

28. Crenolanib [inn]

29. Crenolanib,cp-868596

30. [1-[2-[5-(3-methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine

31. Crenolanib [who-dd]

32. Mls006010956

33. Crenolanib - Cp-868569

34. Gtpl7882

35. Schembl2730601

36. Chembl2105728

37. Dtxsid50985873

38. Ex-a215

39. Chebi:145365

40. Bdbm185149

41. Hms3656f19

42. Bcp02384

43. Zinc3820043

44. Nsc763526

45. Nsc800079

46. S2730

47. Akos026750597

48. Bcp9000551

49. Ccg-264988

50. Cs-0566

51. Db11832

52. Nsc-763526

53. Nsc-800079

54. Sb16603

55. Ncgc00346658-01

56. Ncgc00346658-09

57. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine

58. Ac-32071

59. As-57698

60. Hy-13223

61. Smr004702760

62. Sy237889

63. Ft-0665221

64. Sw218293-2

65. D10102

66. J-502712

67. Q5184160

68. Cp-868596;cp 868596;cp868596;aro 002

69. 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1h-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine

70. 1-{2-[5-(3-methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine

71. 4-piperidinamine, 1-(2-(5-((3-methyl-3-oxetanyl)methoxy)-1h-benzimidazol-1-yl)-8-quinolinyl)-

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₉N₅O₂
Molecular Weight	443.5 g/mol
XLogP3	3.7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	443.23212518 g/mol
Monoisotopic Mass	443.23212518 g/mol
Topological Polar Surface Area	78.4 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	667
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Crenolanib manufacturers, exporters & distributors on PharmaCompass

Crenolanib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

INTERMEDIATES

2 Intermediates Suppliers

DIGITAL CONTENT

1 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

2INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?